Digital quantitative assessment of PD-L1 using digital spatial profiling
- 1 October 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 100 (10), 1311-1317
- https://doi.org/10.1038/s41374-020-0424-5
Abstract
No abstract availableKeywords
Funding Information
- Breast Cancer Research Foundation (BCRF-19-138)
This publication has 21 references indexed in Scilit:
- A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignanciesJournal of Clinical Pathology, 2018
- Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expressionLaboratory Investigation, 2018
- Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of Clinical Oncology, 2017
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyJournal of Clinical Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010